Enliven Therapeutics, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
0.00 |
0.01 |
0.01 |
0.01 |
5.00 |
50.00 |
| Przychód Δ r/r |
0.00% |
inf% |
0.00% |
75.00% |
39900.00% |
900.00% |
| Przychód (min) |
0.00 |
0.01 |
0.01 |
0.01 |
5.00 |
50.00 |
| Przychód (max) |
0.00 |
0.01 |
0.01 |
0.01 |
5.00 |
50.00 |
| EBITDA (średnia) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| EBIT (średnia) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| EBIT % |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| Zysk netto (średni) |
-91.85 |
-100.20 |
-116.67 |
-187.97 |
-144.04 |
-107.66 |
| Zysk netto % |
-inf% |
-1402785.97% |
-1633320.44% |
-1503722.00% |
-2880.79% |
-215.32% |
| EPS (średnia) |
-1.95 |
-2.13 |
-2.48 |
-3.28 |
-3.06 |
-2.29 |
| Liczba analityków (Przychody) |
0 |
5 |
7 |
5 |
1 |
2 |
| Liczba analityków (EPS) |
3 |
2 |
4 |
5 |
2 |
1 |
| symbol |
ELVN |
ELVN |
ELVN |
ELVN |
ELVN |
ELVN |